Clinical Trial Update: EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating the combination of EGFR-TKIs with chemotherapy as first-line therapy for advanced EGFR mutation-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR-TKIs (various)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: EGFR Gene Mutation | Phase 3 | Status: UNKNOWN